A prognostic model for HIV seroconversion among injection drug users as a tool for stratification in clinical trials

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 4, 2005, Pages 489-495

  Boileau, Catherine ^a   Bruneau, Julie ^a,b,c   Al Nachawati, Hicham ^b   Lamothe, François ^a   Vincelette, Jean ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

HIV behavioral risk factors; Injection drug use; Prognostic model; Risk score; Survival study

Indexed keywords

COCAINE;

ADOLESCENT; ARTICLE; BEHAVIOR; DRUG ABUSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RISK FACTOR; RISK MANAGEMENT; SCORING SYSTEM; SEROCONVERSION; VALIDATION PROCESS;

EID: 22344435642     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000153424.56379.61     Document Type: Article

References (47)

1. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86:642-654.
2. Alcabes P, Friedland G. Injection drug use and human immunodeficiency virus infection. Clin Infect Dis. 1995;20:1467-1479.
3. Rhodes T, Lowndes C, Judd A, et al. Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS. 2002;16:F25-F31.
4. Hamers FF, Batter V, Downs AM, et al. The HIV epidemic associated with injecting drug use in Europe: geographic and time trends. AIDS. 1997;11: 1365-1374.
5. Sarkar S, Das N, Panda S, et al. Rapid spread of HIV among injecting drug users in north-eastern states of India. Bull Narc. 1993;45:91-105.
6. Health Canada. HIV and AIDS in Canada, surveillance report to December 31, 2003. Division of HIV/AIDS Epidemiology and Surveillance, Center of Infection Diseases Prevention and Control; Ottawa, Ontario, Canada; 2004.
7. Bruneau J, Lamothe F, Franco E, et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol. 1997;146:994-1002.
8. Strathdee SA, Patrick DM, Archibald CP, et al. Social determinants predict needle-sharing behaviour among injection drug users in Vancouver, Canada. Addiction. 1997;92:1339-1347.
9. Wood E, Tyndall MW, Spittal PM, et al. Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS. 2002;16:941-943.
10. Fisher RI. Overview of non-Hodgkin's lymphoma: biology, staging, and treatment. Semin Oncol. 2003;30:3-9.
11. Haase GM, Perez C, Atkinson JB. Current aspects of biology, risk assessment, and treatment of neuroblastoma. Semin Surg Oncol. 1999;16: 91-104.
12. Mountain CF. Staging classification of lung cancer. A critical evaluation. Clin Chest Med. 2002;23:103-121.
13. Kaneko M, Kanda Y, Oshima K, et al. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan. Ann Hematol. 2002;81:33-36.
14. Resnic FS, Ohno-Machado L, Selwyn A, et al. Simplified risk score models accurately predict the risk of major in-hospital complications following percutaneous coronary intervention. Am J Cardiol. 2001;88: 5-9.
15. Solomon DH, Ganz DA, Avorn J, et al. Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. J Clin Epidemiol. 2002;55:121-128.
16. Mistry FP, Karnad DR, Abraham P, et al. A scoring system to differentiate cirrhotic from non-cirrhotic portal hypertension. Indian J Gastroenterol. 1991;10:82-85.
17. Cheng FK, Ford WL, Weber MD, et al. A probability-based approach for predicting HIV infection in a low prevalent population of injection drug users. Ann Epidemiol. 1997;7:28-34.
18. Shah S, Karnad DR. What's the score? On the development and use of prognostic scores in clinical practice. Indian J Gastroenterol. 2003;22: 43-45.
19. Greenhalgh D, Lewis F. The general mixing of addicts and needles in a variable-infectivity needle-sharing environment. J Math Biol. 2002;44: 561-598.
20. Friedman SR, Jose B, Deren S, et al. Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. The National AIDS Research Consortium. Am J Epidemiol. 1995;142:864-874.
21. Neaigus A, Friedman SR, Jose B, et al. High-risk personal networks and syringe sharing as risk factors for HIV infection among new drug injectors. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:499-509.
22. Jackson LA, Bailey DL, Fraser JR, et al. Safer and unsafe injection drug use and sex practices among injection drug users in Halifax, Nova Scotia. An exploratory look at community and interpersonal influences. Can J Public Health. 2002;93:219-222.
23. Thorpe LE, Bailey SL, Huo D, et al. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997-1999). J Acquir Immune Defic Syndr. 2001;27:71-78.
24. Van Ameijden EJ, Langendam MW, Notenboom J, et al. Continuing injecting risk behaviour: results from the Amsterdam Cohort Study of drug users. Addiction. 1999;94:1051-1061.
25. Grand JP, Friedman SR, Stern LS, et al. Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Soc Sci Med. 1996;42:691-703.
26. Song JY, Safaeian M, Strathdee SA, et al. The prevalence of homelessness among injection drug users with and without HIV infection. J Urban Health. 2000;77:678-687.
27. Alary M, Hankins C, Parent R, et al. SurvIDU Working Group. Risk factors for HIV acquisition among IDUs in the SurvIDU Network: long-term cocaine injectors are those most at risk. Can J Infect Dis. 2000; 11(Suppl B):Abstract No. 302.
28. Anthony JC, Vlahov D, Nelson KE, et al. New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1. Am J Epidemiol. 1991;134:1175-1189.
29. Perron S, Raynault MF, Bruneau J. Frequency of intravenous cocaine bingeing and risk factors associated with HIV transmission. Can J Infect Dis. 2002;13(Suppl A):Abstract NB 336P.
30. Kral AH, Bluthenthal RN, Lorvick J, et al. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001;357:1397-1401.
31. Chitwood DD, Griffin DK, Comerford M, et al. Risk factors for HIV-1 seroconversion among injection drug users: a case-control study. Am J Public Health. 1995;85:1538-1542.
32. Spittal PM, Craib KJ, Wood E, et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. Can Med Assoc J. 2002;166:894-899.
33. Estebanez PE, Russell NK, Aguilar MD, et al. Women, drugs and HIV/AIDS: results of a multicentre European study. Int J Epidemiol. 2000;29:734-743.
34. Kral Ah, Lorvick J, Edlin Br. Sex and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. J Acquir Immune Defic Syndr. 2000;24:162-167.
35. Bruneau J, Lamothe F, Soto J, et al. Sex-specific determinants of HIV infection among injection drug users in Montreal. Can Med Assoc J. 2001;164:767-773.
36. Kral AH, Bluthenthal RN, Erringer EA, et al. Risk factors among IDUs who give injections to or receive injections from other drug users. Addiction. 1999;94:675-683.
37. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
38. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14:1707-1723.
39. Schlichting P, Christensen E, Andersen PK, et al. Prognostic factors in cirrhosis identified by Cox's regression model. Hepatology. 1983;3:889-895.
40. Rex DK. Screening for colon cancer and evaluation of chemoprevention with coxibs. J Pain Symptom Manage. 2002;23:S41-S50.
41. Evans JL, Hahn JA, Page-Shafer K, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health. 2003;80:137-146.
42. Latkin CA, Mandell W, Knowlton AR, et al. Gender differences in injection-related behaviors among injection drug users in Baltimore, Maryland. AIDS Educ Prev. 1998;10:257-263.
43. Dwyer R, Richardson D, Ross MW, et al. A comparison of HIV risk between women and men who inject drugs. AIDS Educ Prev. 1994;6:379-389.
44. Strathdee SA, Galai N, Safaiean M, et al. Sex differences in risk factors for HIV seroconversion among injection drug users: a 10-year perspective. Arch Intern Med. 2001;161:1281-1288.
45. De Irala J, Bigelow C, McCusker J, et al. Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. Am J Epidemiol. 1996;143:725-732.
46. McElrath K, Chitwood DD, Griffin DK, et al. The consistency of self-reported HIV risk behavior among injection drug users. Am J Public Health. 1994;84:1965-1970.
47. Comité Permanent de Lutte à la Toxicomanie. Le Point sur la Situation de la Toxicomanie au Québec en L'An. 2000. Gouvernement du Québec, Ministère de La Santé et des Services Sociaux. Montreal, Québec, Canada: 2001.